02 Apr 2026
Stay one step ahead with Lonza Capsugel at Vitafoods Europe 2026
  • Lonza Capsugel will showcase its plant-based capsules, European manufacturing capabilities, dosage form solution expertise and health ingredients, alongside inspirational product concepts at Vitafoods Europe 2026, booth #3F72.
  • The event marks a new chapter for the company following the divestment of its Capsules & Health Ingredients business to Lone Star Funds.
  • Attendees can hear from Lonza Capsugel’s Senior Director of Sustainability, Sofia Sotiropoulou, on leveraging sustainability for brand differentiation and market leadership.

Barcelona, Spain, 2 April 2026 – At Vitafoods Europe 2026, booth #3F72, Lonza Capsugel will showcase how nutraceutical brands can stay one step ahead with their next supplement innovation. This year’s appearance also comes as the company enters a significant new chapter following the recently signed agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds (‘Lone Star’), marking an important milestone for the company as it continues to strengthen its strategic focus.

Attendees can explore how the company’s high-performing plant-based capsules, European capsule manufacturing capabilities, sustainability credentials, dosage form solutions and health ingredients, alongside inspirational product concepts, can help customers get ahead and stay ahead in the nutraceutical market.

At its booth, Lonza Capsugel will invite visitors to explore:

  • Capsugel® Plantcaps® capsules: Built for premium oxygen protection that lasts, Capsugel® Plantcaps® capsules are the only pullulan capsule designed for both powders and liquid fills.* Their superior oxygen barrier helps brand protect their sensitive ingredients, while also aligning with consumer expectations for clean, sustainable products. With a naturally high-luster finish and no risk of “spotting” concerns, Capsugel® Plantcaps® capsules deliver on performance and visual appeal.
  • The advantages of Made in Europe capsule manufacturing: With close to 94% of its capsules produced in European sites shipped to European customers, Lonza Capsugel supports local manufacturing and reduced carbon emissions** product claims in Europe, as well as end-to-end traceability, from raw material purchasing to consumers.
  • Planet-friendly*** capsule solutions: Aligned with the growing number of consumers seeking more sustainable nutraceutical supplements,i,ii Lonza Capsugel will highlight how it can help customers drive brand trust and differentiation. Sofia Sotiropoulou, Senior Director of Sustainability and Climate Innovation will present "Sustainability by Design: Partnering to Stay One Step Ahead with Lonza Capsugel." on May 5, from 13:35-14:05 at the Vitafoods Europe Insights Theatre. Sofia will demonstrate how Lonza Capsugel uses sustainability and circularity principles to help customers co-create products with a lower environmental impact and reduced carbon footprint through its Center of Applied Sustainability. Additionally, Sofia will present the latest trends shaping the nutraceutical market and how sustainability can be leveraged to build brand differentiation and innovation via products with science-backed and regulatory compliant sustainability credentials. At its booth, Lonza Capsugel will spotlight its investments in decarbonizing manufacturing, particularly at its European facilities in Bornem (Belgium) and Colmar (France), which as of 2025, run on 100% renewable electricity, reinforcing its goal to produce capsule solutions that make a positive difference for its customers and the planet.
  • Science-backed joint health and mobility support for humans and pets: Lonza Capsugel’s UC-II® undenatured type II collagen is clinically shown to improve joint flexibility in healthy adults.iii,iv,v  What’s more, UC-II® undenatured type II collagen is available at different grades for both humans and dogs, allowing owners to not only look after their own joint health but also that of their companion animals. UC-II® Pets offers joint health and mobility support at a low daily dose of 40 mg.vi,vii,ix,x
  • Dosage form solutions expertise: Through its Innovation Services, Lonza Capsugel’s advanced polymer science and capsule technology expertise can help turn complex technical challenges into breakthrough supplements. For instance, its Capsugel® Liquid-Filled capsules provide leak prevention for enhanced ingredient protection while its Capsugel® Beadlets technology supports tailored release profiles that deliver otherwise incompatible ingredients. Capsugel® DUOCAP® Dual Release Capsules combine multiple ingredients into one powerful dose, while also protecting acid-sensitive ingredients and enabling tailored release profiles. As formulation complexity rises across Europe, Lonza Capsugel also brings a unique perspective on how CDMO roles are evolving—sharing insights from working closely with leading manufacturers and supporting brand owners navigating growing technical, regulatory, and clean‑label demands.
  • In-stock and ready-to-go program. When product launches need to be fast, so you can stay ahead of the competition, Lonza Capsugel provides fast shipping. Its colorful capsules can be quickly delivered in a variety of polymers, sizes, and quantities that allow for a timely solution for growing customer demands, exciting market dynamics, and high quality, science-backed products.****

In a rapidly changing world, Lonza Capsugel’s breadth and depth of expertise, along with a strong perspective on future trends and market dynamics, enables it to anticipate the needs of the industry and provide proactive solutions.

Find out more about Lonza Capsugel at Vitafoods Europe 2026, May 5-7. Visitors can book an appointment here to meet with the expert team from Lonza Capsugel at booth #3F72.

Lonza Capsugel Contact Details

Anne Holderbach
Director, Strategic Marketing
Tel +33 76 267 9876

For Media Inquiries: media@lonza.com

Disclaimer
Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used only for informational purposes.

Privacy Policy link

i FMCG Gurus announces their Top Ten Trends for 2025. October 2024. Available at: https://fmcggurus.com/blog/fmcg-gurus-announces-their-top-ten-trends-for-2025/
ii NielsenIQ (2025) The changing story of sustainability. Available at: https://nielseniq.com/global/en/landing-page/tl-the-changing-story-of-sustainability/
iii Schön, C. et al. (2022). UC-II Undenatured Type II Collagen for Knee Joint Flexibility: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study. Journal of integrative and complementary medicine, 28(6), 540–548.
iv Soucie, J. M., et al. (2011). Range of motion measurements: reference values and a database for comparison studies. Haemophilia, 17(3), 500-507.
v Knaub, K. et al. (2022). UC-II® undenatured type II collagen reduces knee joint discomfort and improves mobility in healthy subjects: a randomized, double-blind, placebo-controlled clinical study. Journal of Clinical Trials, 12(1):1000492.
vi Varney et al. (2022). Impact of supplemented undenatured type II collagen on pain and mobility in healthy Labrador Retrievers during an exercise regimen. Transl Anim Sci, 6, 1–7.
vii Varney et al. (2021). Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy dogs during an exercise regimen. Transl Anim Sci, 5, 2.
viii Gupta et al. (2012). Comparative therapeutic efficacy and safety of type-II collagen, glucosamine and chondroitin in arthritic dogs: Pain evaluation by ground force plate: Arthritis treatment in dogs. J Anim Physiol Nutr, 96, 770–777.
ix D’Altilio et al. (2007). Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mech Methods, 17, 189–196.
x Peal et al. (2007). Therapeutic efficacy and safety of undenatured type-II collagen alone or in combination with (-)-hydroxycitric acid and ChromeMate in arthritic dogs. J Vet Pharmacol Ther, 30, 275–278.

*According to market data in 2026.
**Reduced carbon emissions versus global non decarbonized suppliers. Calculation based on product carbon footprint external study, performed in 2024 with 2023 reference data comparing Lonza Capsugel versus weighted average for the rest of market, excluding Lonza. At the time of study, it was assumed that average market was not decarbonized at company level.
***Based on carbon footprint data and transition to renewable electricity.
****Availability, color, and technology offerings vary by region.